Biomarker-Driven Lung Cancer

>

Latest News

Differences in TKIs May Sway Choice of First-Line Therapy in ALK+ NSCLC
Differences in TKIs May Sway Choice of First-Line Therapy in ALK+ NSCLC

May 21st 2024

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, asked participants their perspectives on the use of targeted agents for patients with ALK+ non–small cell lung cancer in the second article of a 2-part series.

Bispecific Combination Therapy Leads Paradigm Shift in Advanced NSCLC
Bispecific Combination Therapy Leads Paradigm Shift in Advanced NSCLC

May 20th 2024

Phase 2 Study of Glecirasib Meets Primary End Point in KRAS G12C-Mutant NSCLC
Phase 2 Study of Glecirasib Meets Primary End Point in KRAS G12C-Mutant NSCLC

April 30th 2024

Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC

April 26th 2024

FDA Approves Adjuvant Alectinib in ALK+ NSCLC
FDA Approves Adjuvant Alectinib in ALK+ NSCLC

April 18th 2024

More News